Sterenn Davis

Sterenn Davis is a Senior Principal Scientist at Adaptimmune, with a robust background in molecular biophysics and single-cell sequencing. Prior to this role, Sterenn served as Team Leader at Theolytics and as Principal Scientist at Immunocore, where contributions included co-founding the Single Cell Technologies group and pioneering single-cell sequencing advancements within the discovery pipeline. Earlier experience as a Senior Scientist at Immunocore involved phage display and the successful introduction of cutting-edge sequencing techniques. Additionally, Sterenn worked as a Research Technician at the UCL Institute of Ophthalmology, playing a key role in the discovery of Magacizumab, a therapeutic monoclonal antibody. Sterenn holds a PhD in Molecular Biophysics and an MPhys in Physics, both from the University of Exeter.